Neobrufen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neobrufen

Property Description
Active ingredient Ibuprofen
Form Tablet, capsule, oral suspension, suppository, topical gel
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic, propionic acid derivative

What Type of Medicine is Neobrufen?

Neobrufen is a medicinal product containing the active ingredient Ibuprofen, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This pharmacological class is defined by its ability to modulate the biological processes that generate pain and inflammation. As an NSAID, the drug is functionally categorized as an analgesic (pain reliever) and an antipyretic (fever reducer). Ibuprofen has an established role in reducing the body's inflammatory response and providing pain relief. This medicine provides general symptomatic relief from discomfort and fever, a utility recognized for its widespread application in treating common acute symptoms.

Composition, Origin, and Available Forms of Ibuprofen

The therapeutically active substance, Ibuprofen, is a synthetic compound derived from the propionic acid group, confirming its chemical origin and structure. Neobrufen is typically formulated as a single-ingredient product, focusing exclusively on the pharmacological effects of Ibuprofen. The product is prepared in various standard dosage forms, including oral options such as coated tablets, capsules, and oral suspension, as well as forms for rectal administration (suppositories) and topical use (gel).

What is Neobrufen's General Therapeutic Purpose?

The general therapeutic purpose of Neobrufen is to reduce inflammation, mitigate associated discomfort, and lower elevated body temperature. Its efficacy stems from its core mechanism: inhibiting the cyclooxygenase (COX) enzyme system, which limits the production of prostaglandins—key chemical messengers responsible for initiating pain and fever signals. Ibuprofen provides relief by interfering with the chemical mediators of inflammation. This application defines its broad benefit across various painful and inflammatory conditions, serving primarily to alleviate general symptoms.

Regulatory References

  1. WHO Essential Medicines List for Ibuprofen
  2. WHO Essential Medicines List
  3. EMA's Ibuprofen safety review
  4. EMA safety update on Ibuprofen

What side effects are possible with Neobrufen?

Possible side effects and safety information

The safety profile of Neobrufen, containing the Non-Steroidal Anti-Inflammatory Drug (NSAID) Ibuprofen, is formally defined in government regulatory documents through classifications of adverse reactions by frequency and affected organ system.

Documented Adverse Reaction Scope

Adverse reactions are formally grouped by System-Organ-Class (SOC). The most common documented effects involve Gastrointestinal Disorders (e.g., dyspepsia, nausea, abdominal pain) and Nervous System Disorders (e.g., headache, dizziness), typically classified as Common in official labeling.

Less frequent (Uncommon or Rare) reactions may involve Immune System Disorders (hypersensitivity reactions), Skin and Subcutaneous Tissue Disorders (rash), or potential effects on the renal and hepatic systems.

Serious Adverse Reactions and Constraints

Official regulatory sources highlight the potential for serious adverse reactions, including an increased risk of gastrointestinal bleeding, ulceration, and perforation, which can occur without warning. Similarly, there is a documented risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which may occur early in treatment.

Safety-Related Restrictions officially contraindicate the medicine in individuals with a history of active GI bleeding or ulceration, severe heart failure, or severe renal or hepatic impairment.

Duration and Population-Specific Safety

The regulatory profile specifies that the risk of serious adverse events is documented as potentially increasing with the duration of use and when higher doses are employed. Older adults are officially recognized as being at a higher risk for serious gastrointestinal adverse reactions. Furthermore, the medicine is officially contraindicated during the third trimester of pregnancy due to documented fetal risk.

This framework of officially classified risks and constraints guides the understanding of the medicine's safety profile, focusing strictly on documented adverse effects and limitations.

Overdose and Emergency Response

Overdose of Neobrufen (Ibuprofen) is formally documented in regulatory sources with defined clinical manifestations. Common presentations primarily affect the Central Nervous System (CNS) and the Gastrointestinal (GI) system, including symptoms such as nausea, vomiting, abdominal pain, drowsiness, lethargy, headache, and tinnitus. Most ingestions lead to only mild or no symptoms; however, the ingestion of substantial quantities can lead to severe toxicity.

Regulatory authorities define severe systemic toxicity, which warrants immediate attention. Life-threatening outcomes include acute kidney failure, profound CNS depression leading to convulsions or coma, severe gastrointestinal bleeding or perforation, metabolic acidosis, and respiratory depression. Fatal outcomes have been documented in rare but severe cases of intoxication.

Due to the absence of a specific antidote for acute NSAID toxicity, official guidance mandates that individuals seek immediate medical attention and contact a Poison Control Center right away if an overdose is suspected or if more than the maximum recommended dose has been taken. Management requires hospitalization for symptomatic and supportive treatment, including monitoring of vital signs and laboratory parameters, such as renal function.

Specific regulatory notes address populations with increased risk. Elderly patients are at heightened risk for serious GI complications, while dehydrated children and adolescents have a documented increased risk of renal impairment following an overdose.

Therapeutic Uses of Neobrufen

Neobrufen (Ibuprofen) is commonly used across domains where short-term symptom management is appropriate. Its utility is applied in contexts marked by increased discomfort or tension, which may assist with symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved comfort during periods of heightened symptoms.


Easing Pain and Reducing Fever

This medication is relevant for easing symptoms related to physical discomfort and systemic imbalance. Neobrufen is commonly used to help with pain associated with headaches, dental pain, muscular aches, and menstrual cramps (dysmenorrhoea), and plays a role in managing fever, a symptom related to systemic imbalance.


Support for Inflammation and Episodic Symptoms

Neobrufen is considered relevant in conditions characterized by periods of heightened symptoms, particularly those involving inflammatory or irritative states like flares of osteoarthritis and rheumatoid arthritis. It is applied for recurrent manifestations like dysmenorrhoea and during recovery from minor sprains or dental procedures, addressing symptoms that create noticeable physiological strain.

“It supports patients during episodes of heightened discomfort by easing distress when symptoms interfere with routine activities.”

Quick Fact: Support for Pain, Inflammation, and Fever : Neobrufen is applicable within clinical settings that involve acute or disruptive symptom patterns, helping to address symptom clusters that may become intense or disruptive and assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Official Population Eligibility for Neobrufen

Regulatory documents define eligibility for Neobrufen (Ibuprofen) based on pre-existing conditions, age, and physiological status. The medicine is contraindicated and must not be used by several population groups, as determined by health authorities.


Eligibility Status Population Rule (Official Regulatory Basis)
Contraindicated Patients with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure.
Individuals with active or a history of recurrent peptic ulcer or gastrointestinal haemorrhage.
Patients with a history of hypersensitivity reactions (e.g., asthma, angioedema) to Ibuprofen or other NSAIDs/Aspirin.
Use during the third trimester of pregnancy (beginning at 30 weeks gestation).
Restricted Use Older adults (ge 60 years) are at greater risk of adverse events and must use the lowest dose for the shortest duration.
Use in patients with mild-to-moderate organ impairment or established cardiovascular disease (NYHA Class II-III) is restricted, and high doses (ge 2,400 mg/day) are generally avoided.
Age Threshold Approved use for standard oral formulations begins at 12 years of age; specific tablets are contraindicated below 20 kg body weight (or younger than 6 years).

This structure reflects the regulatory classification used in official government labeling to define who is permitted to use the medicine, who is ineligible due to absolute contraindications, and who requires use under restricted or conditional circumstances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns for Neobrufen (Ibuprofen) as listed in authoritative government regulatory documentation.

Interaction Category Officially Documented Information
Medicinal Product Categories Other NSAIDs (including COX-2 inhibitors), Anticoagulants (e.g., Warfarin), Diuretics, Antihypertensives (ACE inhibitors, ARBs), Oral Corticosteroids, and SSRIs.
Specific Interacting Medicines Acetylsalicylic acid (Aspirin) (both low and high dose), Lithium, Methotrexate, and Alcohol (Ethanol).

Classification Regulatory Statement / Constraint
Severity Classification Contraindicated with other NSAIDs and high-dose Aspirin.
Timing Rules Should be administered at least 30 minutes after or 8 hours before immediate-release low-dose Aspirin to mitigate interference with Aspirin's anti-platelet effect.

Official Interaction Statements

Co-administration with other NSAIDs is formally contraindicated due to an increased risk of serious gastrointestinal adverse events. Neobrufen reduces the renal clearance of substances like Lithium and Methotrexate, potentially leading to elevated plasma concentrations and accumulation. The drug can also enhance the effects of Anticoagulants and increase the risk of bleeding. Regulatory labeling notes that Ibuprofen may reduce the antihypertensive and diuretic effects of those classes of medicines. Furthermore, the consumption of Alcohol is documented to increase the risk of stomach bleeding.

Connection to the Overall Interaction Profile:

Official regulatory documents define the interaction structure by listing contraindicated combinations and identifying agents whose clearance is significantly affected by Ibuprofen's activity in the kidney, such as Lithium and Methotrexate. Several pharmacodynamic interactions are noted for increasing the risk of bleeding or reducing the efficacy of cardiovascular medicines.

Mechanism of Action

Neobrufen (ibuprofen) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that exerts its effect by targeting specific biological enzymes responsible for modulating biological processes associated with increased local mediator production and thermoregulation. This action fundamentally shifts the balance of chemical mediators within the body, leading to modulations of signal transduction cascades.


Inhibition of Cyclooxygenase (COX) Enzymes

This mechanism describes the drug's primary molecular interaction, which is the reversible inhibition of the COX-1 and COX-2 enzymes. By blocking these key catalytic sites, the drug prevents the conversion of arachidonic acid, thereby interfering with an early molecular step crucial for systemic physiological outcomes.


Modulating Prostaglandin and Thromboxane Synthesis

The functional consequence of COX inhibition is the marked reduction in the synthesis of prostaglandins and thromboxanes, which are potent mediators of nociceptive signaling, hypothalamic thermoregulation, and localized vascular responses. The inhibition of mediator synthesis suppresses the propagation of signals, leading to a decrease in pathway activation, and affecting the equilibrium of signal transduction within the targeted pathways.


Consequent Physiological Adjustments in Nociception and Thermoregulation

This domain covers the resulting physiological adjustments: the diminished prostaglandin levels alter the prostaglandin-mediated amplification of nociceptive input and dampen the thermoregulatory center in the hypothalamus. This targeted pathway interference produces resulting physiological adjustments, which determines the downstream physiological effects related to diminished nociceptive input and modulation of hypothalamic thermoregulatory set-point.

Dosage and Administration Information

How to Use Neobrufen

Neobrufen, containing the active substance Ibuprofen, is administered according to standardized protocols to provide structured symptomatic relief. Usage principles are defined by administration route, specific dosing ranges, and duration constraints.


Official Routes and Administration Time

The medicine is available for several routes, with the most common being Oral administration via tablets, capsules, or suspension. It is also available as an Intravenous (IV) Infusion for use in institutional settings and for Rectal and Topical application. Oral doses may be taken with or after food or milk to potentially lessen gastrointestinal discomfort.


Dosing and Duration Principles

Administration frequency is defined by the intended use. For acute symptoms, doses are typically taken every 4 to 6 hours as needed. For long-term use in inflammatory conditions, the dosage is usually divided and taken 3 to 4 times daily. A core principle is the use of the lowest effective dose for the shortest duration necessary for relief.

Usage Category Administration Guidelines
OTC Maximum Daily Dose Limited to 1,200 mg (unless directed otherwise)
Prescription Maximum Daily Dose Up to 3,200 mg per day
Duration Limit (OTC) Not more than 10 days for pain or 3 days for fever
Pediatric Dosing Based on patient weight, not to exceed 40 mg/kg/day

If a dose is missed, it should be skipped if the next scheduled dose is near; do not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neobrufen


Evidence for Use in Acute Pain and Fever

Research on Neobrufen (Ibuprofen) is primarily derived from numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time during acute episodes of discomfort, including headache, dental pain, and menstrual cramps (dysmenorrhoea). Studies also explored temporary physiological imbalance by examining outcomes related to elevated body temperature (fever). Researchers focused on adults experiencing short-term, mild-to-moderate discomfort and on pediatric patients for fever management.

Findings describe patterns observed in the studies related to how pain outcomes were measured. The evidence base also includes many Systematic Reviews and Meta-analyses that combine data from multiple RCTs, which generally contribute to the broader evidence landscape for understanding acute symptom patterns.

Evidence for Use in Inflammatory Musculoskeletal Conditions

Neobrufen was evaluated in studies examining symptomatic response for conditions involving periods of heightened symptoms, particularly those linked to inflammatory or irritative states like flares of osteoarthritis and rheumatoid arthritis. Research examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level in adults diagnosed with chronic musculoskeletal conditions.

Studies monitored how symptoms evolved in the observed populations, and findings indicate patterns related to the changes observed in physical function scores (such as the WOMAC Index) in subjects with arthritis during the study period. The body of evidence for exploring symptom patterns in these contexts is substantial, though the follow-up durations were limited in many controlled trials, typically extending to only six weeks.


What is Still Uncertain About Neobrufen

The research landscape highlights several areas where certainty remains low or where more studies are needed. One key limitation is that comparative evidence is lacking for certain highly specific combinations of pain type and dosage. Also, the research conducted for acute uses generally focused on examining short-term symptom changes, resulting in limited information for long-term outcomes. Additionally, because the study results reflect the specific conditions under which they were conducted, the research provides context but not individual predictions.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Osteoarthritis: care and management

Frequently Asked Questions (FAQ)

Common questions about Neobrufen (FAQ)


Q: How does Neobrufen compare to standard ibuprofen tablets?

Regulatory bodies consider all generic medicines, including standard ibuprofen tablets, which contain the same active ingredient at the same strength, to be clinically equivalent to branded products like Neobrufen. Both are required to meet the same high regulatory standards for quality, safety, and performance.


Q: Why might a doctor prescribe Neobrufen instead of just ibuprofen?

Official prescribing guidance confirms that the active ingredient, ibuprofen, is the same in both branded and generic products. Prescribing by brand name may relate to ensuring a specific formulation or strength is received, or to maintain consistency with the medication the patient is currently using, as confirmed by official prescribing information.


Q: Is it normal to feel a slight stomach discomfort after taking Neobrufen?

Official product information classifies certain gastrointestinal issues as Common side effects. These frequently documented effects can include dyspepsia (indigestion), nausea, or abdominal pain. Regulatory guidance suggests oral doses may be taken with or after food or milk, which is often done to potentially lessen gastrointestinal discomfort.


Q: Is Neobrufen safe for people who have mild high blood pressure?

Regulatory documents state that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like Neobrufen can potentially reduce the effectiveness of certain blood pressure medications (antihypertensives). Use in patients with cardiovascular risk factors is restricted, and official labeling mandates that it be used with caution and only after consideration of these risks.


Q: Why does the packaging for Neobrufen mention risks for heart conditions?

Regulatory labeling includes a serious warning about the potential for an increased risk of serious cardiovascular thrombotic events, which include heart attack (myocardial infarction) and stroke. These warnings reflect the documented risks associated with NSAID use, which are required by regulatory bodies to be prominently displayed on product labeling.


Q: Can a patient with asthma use Neobrufen safely?

Official guidelines state that Neobrufen is contraindicated (must not be used) in patients who have a history of hypersensitivity reactions, such as asthma, angioedema, or hives, caused by ibuprofen or other NSAIDs/Aspirin. This restriction is based on documented adverse events related to hypersensitivity reactions to NSAIDs.


Q: Is Neobrufen the same as other branded Ibuprofen drugs?

All medicines containing ibuprofen as the active ingredient are required to meet strict regulatory standards for therapeutic equivalence. This means that while the brand names differ, the chemical compound, dosage, safety profile, and expected effect are officially considered the same as other equivalent ibuprofen products.


Q: What is the difference between Neobrufen and naproxen?

Both Neobrufen (ibuprofen) and naproxen belong to the same pharmacological class: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Both primarily work by inhibiting the cyclooxygenase (COX) enzyme system. Regulatory documents classify them similarly, although they are different chemical compounds and may have different administration schedules.


Q: Is it okay to drive or operate machinery after taking Neobrufen?

Official product information notes that some common side effects can include central nervous system effects such as dizziness or headache. Patients who experience these or other CNS effects are advised to exercise caution when engaging in activities like driving or operating machinery.


Q: Can Neobrufen be crushed or chewed if someone has trouble swallowing pills?

The official product line for ibuprofen often includes different pharmaceutical forms, such as oral suspension (liquid), which is specifically intended for patients who have difficulty swallowing tablets or capsules. Specific regulatory instructions regarding crushing or chewing the solid tablets are not provided in the product information.


Q: Are there any known interactions between Neobrufen and herbal supplements?

While regulatory documents primarily list drug-to-drug interactions, some authoritative resources advise caution with certain herbal supplements (such as Ginkgo Biloba or Garlic) that may possess anti-platelet properties. This introduces a potential interaction risk when taken alongside an NSAID like Neobrufen.


Q: Are there different strengths or formulations of Neobrufen available?

Yes, official regulatory documents indicate that Neobrufen (ibuprofen) is supplied in multiple dosage forms and strengths. These typically include different milligram strengths of oral tablets, capsules, and a liquid oral suspension.


Q: What is the maximum number of days Neobrufen should be taken consecutively?

For over-the-counter (OTC) use, official guidelines recommend limiting administration to no more than 10 days for pain or 3 days for fever consecutively. Continued use beyond these durations requires professional guidance.


Q: Is Neobrufen often used for chronic pain management?

Regulatory warnings emphasize the mandate to use the lowest effective dose for the shortest duration necessary for relief. This guidance is due to the documented increase in the risk of serious adverse events (such as gastrointestinal and cardiovascular issues) that occurs with prolonged use.


Q: Does Neobrufen help with nerve pain?

The approved indications for Neobrufen are for symptomatic relief of general pain, fever, and inflammation, which typically excludes nerve pain (neuropathic pain) as a primary indication. The medicine is primarily used for pain arising from inflammation.


Q: How does the mechanism of action for Neobrufen differ from paracetamol?

Neobrufen is primarily a Non-Steroidal Anti-Inflammatory Drug (NSAID) that works by reversibly inhibiting the COX enzymes to reduce prostaglandin synthesis. Paracetamol's primary mechanism of action is understood to be more focused on the central nervous system, and it does not share the same level of peripheral anti-inflammatory action as Neobrufen.


Q: Is Neobrufen more effective against inflammation or just pain?

Neobrufen is officially classified as both an analgesic (pain reliever) and an anti-inflammatory drug. Its action targets the reduction of prostaglandins, which are key chemical messengers that mediate both pain signals and inflammatory processes, confirming its dual nature.


Q: Does Neobrufen cause stomach ulcers in all users?

No. Official regulatory warnings state that Neobrufen can increase the risk of serious gastrointestinal adverse events, including ulceration, which can occur without warning. However, this risk is cited as increasing with duration of use and higher doses, not as a universal outcome for all users.


Q: What is the shelf life of Neobrufen tablets?

Regulatory documents define a specific expiry date (or shelf life) for the product to guarantee its stability and potency over time. This date is determined by the manufacturer and is required to be printed directly on the original packaging.


Q: Are there specific symptoms that mean I should stop taking Neobrufen immediately?

Official labeling states that if symptoms of a serious adverse event occur, the medicine should be discontinued. These symptoms may include signs of gastrointestinal bleeding (e.g., black or tarry stools, vomiting blood) or symptoms of a cardiovascular event (e.g., chest pain, difficulty breathing).


Q: Is Neobrufen considered a strong or mild pain reliever?

Neobrufen (ibuprofen) is generally approved for the relief of mild to moderate pain, fever, and inflammation. This classification is based on its effectiveness for common, short-term symptoms as defined by regulatory indications.


Q: Does Neobrufen have a special coating or release mechanism?

Official documentation lists various pharmaceutical formulations, which can include products like film-coated tablets or capsules. The product information indicates that different authorized products may utilize specialized coatings or formulations designed for protection or ease of swallowing.


Q: How often can Neobrufen typically be taken?

For the symptomatic relief of pain and fever, the standard frequency outlined in regulatory documents is generally a dose taken every 4 to 6 hours as needed.


Q: Is Neobrufen effective for dental pain or post-extraction swelling?

Official regulatory documents and clinical studies list the use of Neobrufen (ibuprofen) for the treatment of dental pain. Its use for general postoperative pain is also documented.


Q: Can Neobrufen be used for back pain relief?

Yes, regulatory documents explicitly list the use of Neobrufen (ibuprofen) for the temporary relief of pain associated with common conditions such as backache.


Q: Is Neobrufen often used for postoperative pain?

Official indications and studies confirm the medicine is used for treating and managing pain relief after surgery (postoperative pain).

How should Neobrufen be stored and disposed of?

Official Storage and Handling Requirements

Regulatory documents define specific conditions to maintain the stability of Neobrufen (ibuprofen). For many tablet formulations, the required storage temperature is not above 25 C or 30 C, although some authorized forms may require no special storage conditions. The medicine must be stored in the original package to ensure protection from moisture and other ambient factors.

All medicinal products must be kept out of the sight and reach of children, as mandated by regulatory bodies to prevent accidental ingestion.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. The product should not be discarded via wastewater or household waste to prevent environmental contamination, necessitating disposal through established community take-back programs or pharmacies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neobrufen found in:

A-Z Index: